Author
Listed:
- Chun Yew Fong
(Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
- Omer Gilan
(Peter MacCallum Cancer Centre
The University of Melbourne)
- Enid Y. N. Lam
(Peter MacCallum Cancer Centre)
- Alan F. Rubin
(The Walter & Eliza Hall Institute of Medical Research
University of Melbourne)
- Sarah Ftouni
(Peter MacCallum Cancer Centre)
- Dean Tyler
(Peter MacCallum Cancer Centre
The University of Melbourne)
- Kym Stanley
(Peter MacCallum Cancer Centre)
- Devbarna Sinha
(Peter MacCallum Cancer Centre)
- Paul Yeh
(Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
- Jessica Morison
(Cambridge Institute for Medical Research and Wellcome Trust-MRC Stem Cell Institute)
- George Giotopoulos
(Cambridge Institute for Medical Research and Wellcome Trust-MRC Stem Cell Institute)
- Dave Lugo
(Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre)
- Philip Jeffrey
(Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre)
- Stanley Chun-Wei Lee
(Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
- Christopher Carpenter
(Cancer Epigenetics DPU, Oncology R&D, GlaxoSmithKline)
- Richard Gregory
(Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre)
- Robert G. Ramsay
(Peter MacCallum Cancer Centre
The University of Melbourne)
- Steven W. Lane
(QIMR Berghofer Medical Research Institute, University of Queensland)
- Omar Abdel-Wahab
(Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
- Tony Kouzarides
(Gurdon Institute and Department of Pathology)
- Ricky W. Johnstone
(Peter MacCallum Cancer Centre
The University of Melbourne)
- Sarah-Jane Dawson
(Peter MacCallum Cancer Centre
The University of Melbourne)
- Brian J. P. Huntly
(Cambridge Institute for Medical Research and Wellcome Trust-MRC Stem Cell Institute)
- Rab K. Prinjha
(Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre)
- Anthony T. Papenfuss
(Peter MacCallum Cancer Centre
The University of Melbourne
The Walter & Eliza Hall Institute of Medical Research
University of Melbourne)
- Mark A. Dawson
(Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
Abstract
BET inhibitors that target bromodomain chromatin readers such as BRD4 are being explored as potential therapeutics in cancer; here, in a MLL–AF9 mouse leukaemia model, resistance to BET inhibitors is shown to emerge from leukaemia stem cells, and be partly due to increased Wnt/β-catenin signalling.
Suggested Citation
Chun Yew Fong & Omer Gilan & Enid Y. N. Lam & Alan F. Rubin & Sarah Ftouni & Dean Tyler & Kym Stanley & Devbarna Sinha & Paul Yeh & Jessica Morison & George Giotopoulos & Dave Lugo & Philip Jeffrey & , 2015.
"BET inhibitor resistance emerges from leukaemia stem cells,"
Nature, Nature, vol. 525(7570), pages 538-542, September.
Handle:
RePEc:nat:nature:v:525:y:2015:i:7570:d:10.1038_nature14888
DOI: 10.1038/nature14888
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Di Yu & Yingying Liang & Claudia Kim & Anbalagan Jaganathan & Donglei Ji & Xinye Han & Xuelan Yang & Yanjie Jia & Ruirui Gu & Chunyu Wang & Qiang Zhang & Ka Lung Cheung & Ming-Ming Zhou & Lei Zeng, 2023.
"Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma,"
Nature Communications, Nature, vol. 14(1), pages 1-16, December.
- Keith Woodley & Laura S. Dillingh & George Giotopoulos & Pedro Madrigal & Kevin M. Rattigan & Céline Philippe & Vilma Dembitz & Aoife M. S. Magee & Ryan Asby & Louie N. van de Lagemaat & Christopher M, 2023.
"Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death,"
Nature Communications, Nature, vol. 14(1), pages 1-19, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:525:y:2015:i:7570:d:10.1038_nature14888. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.